Every weight loss medication has trade-offs. Understanding the specific side effect profile of each class helps you choose the one you'll actually stick with.
The side effects that matter aren't always the ones with the highest incidence rates. What matters is whether you can tolerate them long enough for the medication to work. A medication that causes temporary nausea for 2 weeks during dose escalation has a very different tolerability profile than one that causes persistent cognitive fog for as long as you take it.
Here's how the four major weight loss medication classes compare.
| Category | GLP-1s | Contrave | Qsymia | Orlistat |
|---|---|---|---|---|
| Most common | Nausea (40–44%) | Nausea (33%), constipation (19%) | Tingling (21%), dry mouth (19%) | Oily stool (27%), flatulence (24%) |
| Most disruptive | Vomiting, diarrhea | Insomnia, headache | Cognitive fog, taste changes | Fecal urgency, oily spotting |
| Timeline | Worst during dose escalation, usually improves | Persistent for many users | Persistent (topiramate-related) | Persistent if eating fat |
| Most serious | Pancreatitis (rare), gallbladder events | Suicidality (black box), seizures | Birth defects, metabolic acidosis | Rare liver injury |
| Discontinuation rate (side effects) | 5–7% | ~24% | ~17% | ~4% |
The side effect story for semaglutide, tirzepatide, and liraglutide is dominated by the gastrointestinal tract. GLP-1s slow gastric emptying, which is how they reduce appetite — but this same mechanism causes nausea, vomiting, diarrhea, constipation, and abdominal pain.
Nausea is the headline side effect, reported by 40–44% of patients on semaglutide 2.4mg (Wegovy) in clinical trials. But context matters: most nausea is mild to moderate, peaks during dose escalation (the first 2–4 weeks at each new dose level), and improves as your body adjusts. The "first dose is worst" phenomenon is real — many patients who push through the initial weeks find that nausea becomes manageable or disappears entirely.
Vomiting affects about 24% of Wegovy patients and 13% on Zepbound. Diarrhea hits roughly 30% on Wegovy and 21% on Zepbound. Constipation is reported by about 24% on Wegovy.
The good news: slow titration (gradually increasing the dose over 16–20 weeks) dramatically reduces the severity and duration of these effects. Providers who rush titration to get faster weight loss are doing their patients a disservice. The GLP-1 medications with the best-tolerated dose escalation schedules — tirzepatide's 5-dose ramp over 20 weeks being the gentlest — tend to have lower discontinuation rates.
Weeks 1–4 (starting dose): Mild nausea, reduced appetite. Most patients tolerate this well.
Dose escalation phases: Each step up may trigger 1–2 weeks of increased nausea. This is normal and expected.
Maintenance dose: Most GI side effects stabilize or resolve. Long-term tolerability is generally good.
Red flags at any point: Severe, persistent vomiting; signs of dehydration; severe abdominal pain radiating to the back (pancreatitis). Contact your provider immediately.
Contrave's most distinctive feature isn't its side effect profile — it's the black box warning. The bupropion component carries an FDA black box warning for suicidal thoughts and behavior, particularly in young adults under 25. This is the same warning that appears on standalone bupropion (Wellbutrin) and all other antidepressants.
Beyond the boxed warning, Contrave's day-to-day side effects are split between its two components. Naltrexone contributes nausea (33%), which is the most common reason for discontinuation. Bupropion adds insomnia (9%), dry mouth (8%), headache (18%), and constipation (19%). Unlike GLP-1 nausea, Contrave nausea doesn't reliably improve with time — it persists for many users throughout treatment.
The combination also raises blood pressure slightly in some patients (average 1–2 mmHg increase), which is the opposite of what GLP-1s do. Blood pressure monitoring is recommended, especially in the first 3 months.
The discontinuation rate from side effects is roughly 24% — considerably higher than GLP-1s at 5–7%.
Qsymia's topiramate component creates a unique side effect profile that many patients find harder to tolerate than GI issues. Topiramate is an anti-seizure medication repurposed for weight loss, and its neurological effects are hard to miss.
Paresthesia (tingling) in the hands and feet affects about 21% of patients — it's caused by topiramate's carbonic anhydrase inhibition. Cognitive impairment — difficulty with word-finding, concentration, and memory — is reported frequently and is the most common reason patients stop Qsymia. Patients often describe it as "brain fog" or "feeling dumb." Taste changes (dysgeusia) affect about 10%, typically making carbonated drinks taste flat and certain foods taste metallic.
These neurological effects are dose-dependent and persistent. Unlike GLP-1 nausea, they don't tend to improve with time — they're present for as long as you take the medication. For patients in cognitively demanding jobs, this trade-off may not be worth the 7–10% average weight loss that Qsymia delivers.
Qsymia also carries risks of metabolic acidosis (topiramate reduces bicarbonate levels), increased resting heart rate (phentermine), and kidney stone formation.
Orlistat (Alli over-the-counter, Xenical prescription) blocks fat absorption by inhibiting pancreatic lipase. Its side effects are almost entirely gastrointestinal — and almost entirely tied to how much fat you eat.
Oily or fatty stool (steatorrhea) occurs in about 27% of patients. Oily spotting on underwear — uncontrolled leakage of oily residue — affects a significant number of users and is the most socially disruptive side effect of any weight loss medication. Fecal urgency and flatulence with discharge round out the GI profile.
The mechanism is straightforward: if orlistat blocks 30% of dietary fat absorption, that fat has to go somewhere. It exits unabsorbed in your stool. Eat a low-fat meal, and side effects are minimal. Eat a high-fat meal, and you may need a change of clothes.
Some patients actually view this as a feature rather than a bug — the immediate, unpleasant consequences of eating high-fat foods create a powerful behavioral deterrent. But for most people, the social embarrassment risk limits real-world adherence.
Orlistat also reduces absorption of fat-soluble vitamins (A, D, E, K), so supplementation is recommended.
The "best" weight loss medication isn't the one with the fewest side effects on paper — it's the one whose side effects you can manage while still functioning in your daily life. A few considerations:
If temporary GI discomfort is tolerable: GLP-1s have the best efficacy-to-side-effect ratio. Most side effects improve with time, and the 15–22% weight loss far exceeds other options.
If you can't tolerate nausea: Qsymia's side effects are mostly neurological, not GI. The trade-off is cognitive fog and tingling rather than stomach issues.
If you want minimal systemic effects: Orlistat works entirely in the gut and has almost no systemic absorption. But the GI effects are socially limiting.
If you also need antidepressant effects: Contrave's bupropion component can treat co-existing depression, potentially addressing two conditions with one medication. But the black box warning and higher discontinuation rate are worth weighing.
The providers below offer consultations that match medication choice to your personal tolerance and health profile:
$350 CPA — GLP-1 weight loss programs
Slow titration protocols that minimize GI side effects during dose escalation. Provider follow-up during each dose change.
Get Started →$228 — physician-guided programs
Personalized medication selection based on your health history, side effect tolerance, and treatment goals.
Learn More →Affordable GLP-1 access
Transparent pricing with medical oversight to help manage side effects and adjust dosing as needed.
Check Availability →